STOKStoke Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $184M
- 405% YoY
- Operating margin
- -11.2%
- 96% YoY
- EBITDA
- −$19M
- 81% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired17% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | — | $12M | $9M | $37M | $184M | 405% |
| Operating income | −$86M | −$104M | −$115M | −$101M | −$21M | 80% |
| Net income | −$86M | −$101M | −$105M | −$89M | −$7M | 92% |
| Operating cash flow | −$67M | −$32M | −$81M | −$87M | $46M | 152% |
| Capex | $1M | $4M | $2M | $203K | $670K | 230% |
| Stock-based comp | $16M | $23M | $25M | $27M | $32M | 17% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $44K · 2
- Net
- −$44K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 344 | — |
| FY2024 | — | — | 120 | — |
| FY2023 | — | — | 57 | — |